Corbus Pharmaceuticals Holdings, Inc.

CRBP

CIK 0001595097 · Quarterly mode · latest period FY2024 (Q3) (ending 2024-09-30) · sourced from SEC EDGAR

At a glance · FY2024 (Q3)

Revenue
$1M
↑+447.9% +$972Kvs FY2023 (Q3)
Gross Profit
$1M
↑+447.9% +$972Kvs FY2023 (Q3)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
50/100
  • Profitability
    0ROIC -46.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 8.07 (above 1.5 = solid)
  • Leverage
    100D/E 0.00 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover -0.06x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +447.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$7K
investment in PP&E
Stock-based comp (TTM)
$6M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$168M
everything owned
Total liabilities
$21M
everything owed
Stockholders' equity
$148M
shareholder claim
Net debt
$-28M
Net cash position ($28M)

Recent performance · 50 quarters

Revenue↑+447.9% +$972K
$1M
Net Income↓-69.4% -$10M
$-23M
Free Cash Flow
$-7K
Operating Margin↑+3068.3pts
-1304.0%

Drill down